Shenzhen Kangtai Biological Products Co., Ltd. is a company located in Shenzhen, China. It was established in 1992 and focuses on the research, production, and sales of human vaccines. In February 2017, the company went public on the Shenzhen Stock Exchange's Growth Enterprise Market (stock code: 300601), becoming the first listed vaccine company in South China. The company has its headquarters in Shenzhen and has five major research and industrial bases in Beijing and Shenzhen. These include the headquarters base in Nanshan District, the new vaccine research and production base in Nanshan District, the Kangtai Biological Park in Guangming District, the Minhai Biological Vaccine Industrial Base, and the Minhai Biological New Vaccine International Industrial Base. The company has a leading production scale in the domestic vaccine industry and its marketing and distribution network covers 31 provinces, autonomous regions, and municipalities in China. Over the past 30 years, Kangtai Biological has developed into a high-tech enterprise with a complete range of research and development, rich product lines, and significant technological advantages. It has the capabilities to research and produce viral vaccines, bacterial vaccines, genetic engineering vaccines, combination vaccines, and multi-valent vaccines. The company has six products that have been listed and obtained drug registration approvals. Among them, the 60 micrograms hepatitis B vaccine is a global first, and the acellular pertussis bivalent influenza hemophilus influenzae combined vaccine (quadrivalent vaccine) is exclusive in China. For the hepatitis B vaccine alone, Kangtai Biological has produced and sold over 1.2 billion doses, helping more than 400 million people avoid the invasion of the hepatitis B virus and reducing public health expenditures by over 160 billion yuan, which has significant economic and social value. The company holds more than 50 patents and has over 30 research and development projects, covering key vaccine varieties globally. In terms of international cooperation, the company has extensive technical cooperation with internationally renowned biopharmaceutical companies such as Merck from the United States, Intravacc from the Netherlands, Sanofi Pasteur from France, and AstraZeneca from the United Kingdom. It brings world-leading biotechnology to China and innovates on the basis of digestion and absorption, laying a solid foundation for Chinese vaccines to enter the world stage and participate in international competition. Amid the current COVID-19 pandemic, Kangtai Biological has taken on the responsibility of fighting the epidemic. Its independently developed inactivated COVID-19 vaccine was granted emergency use authorization in May 2021. The internationally introduced adenovirus vector COVID-19 vaccine is actively progressing in domestic clinical registration, production, and commercialization. The company has also made significant progress in the research and development of COVID-19 variant vaccines and mRNA vaccine technology. Looking ahead, Kangtai Biological will continue its mission of "creating better vaccines for the benefit of human health." It will prioritize quality and safety, be driven by research and development innovation, and strive to become a leading domestic and internationally renowned multinational biopharmaceutical company, making greater contributions to safeguarding the lives and health of the people.
Basic Information
Key Executives
Ownership Details
Subsidiaries